Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N D James

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Oncology Reports|September 18, 2004
CD40 expression in prostate cancer: a potential diagnostic and therapeutic moleculeD H Palmer, S A Hussain, R Ganesan, et al.
British Journal of Cancer|May 20, 2004
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancerS A Hussain, D D Stocken, D R Peake, et al.
British Journal of Cancer|August 5, 2004
A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancerS A Hussain, D D Stocken, P Riley, et al.
British Journal of Cancer|September 3, 2010
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancerJ-F Rossi, S Négrier, N D James, et al.
British Journal of Cancer|December 1, 1992
Outcome of children with resistant and relapsed Hodgkin's diseaseN D James, J E Kingston, P N Plowman, et al.
Neurobiology of Aging|March 1, 1996
Neurodegenerative changes including altered tau phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase MosN D James, D R Davis, J Sindon, et al.
British Journal of Cancer|April 18, 2013
Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinomaN J Shimwell, R T Bryan, W Wei, et al.
British Journal of Cancer|February 27, 2015
Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAMR T Bryan, H L Regan, S J Pirrie, et al.
British Journal of Cancer|December 3, 2013
Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potentialR T Bryan, N J Shimwell, W Wei, et al.
Scientific Reports|January 19, 2023
Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detectionL Baxter, N S Gordon, S Ott, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Oncology Reports|September 18, 2004
CD40 expression in prostate cancer: a potential diagnostic and therapeutic moleculeD H Palmer, S A Hussain, R Ganesan, et al.
British Journal of Cancer|May 20, 2004
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancerS A Hussain, D D Stocken, D R Peake, et al.
British Journal of Cancer|August 5, 2004
A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancerS A Hussain, D D Stocken, P Riley, et al.
British Journal of Cancer|September 3, 2010
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancerJ-F Rossi, S Négrier, N D James, et al.
British Journal of Cancer|December 1, 1992
Outcome of children with resistant and relapsed Hodgkin's diseaseN D James, J E Kingston, P N Plowman, et al.
Neurobiology of Aging|March 1, 1996
Neurodegenerative changes including altered tau phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase MosN D James, D R Davis, J Sindon, et al.
British Journal of Cancer|April 18, 2013
Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinomaN J Shimwell, R T Bryan, W Wei, et al.
British Journal of Cancer|February 27, 2015
Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAMR T Bryan, H L Regan, S J Pirrie, et al.
British Journal of Cancer|December 3, 2013
Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potentialR T Bryan, N J Shimwell, W Wei, et al.
Scientific Reports|January 19, 2023
Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detectionL Baxter, N S Gordon, S Ott, et al.
Pageof 6